L-nucleoside enantiomers as antivirals drugs: a mini-review.
The discovery that some nucleoside analogues endowed with the unnatural L-configuration can possess biological activities has been a significant breakthrough in antiviral chemotherapy. In this regard, lamivudine (3TC) was the first L-nucleoside enantiomer approved against HIV and HBV, and several other L-nucleosides are currently under clinical development as antiviral agents.